The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

May 29, 2019

Banu Arun, MD, discusses how the role of genetic testing is evolving in breast cancer with the development of new targeted agents.

May 24, 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses emerging treatment strategies in mantle cell lymphoma.

May 23, 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the InnovaTV 201 trial in cervical cancer.

May 22, 2019

Funda Meric-Bernstam, MD, chair, Department of Investigational Cancer Therapeutics, medical director, Institute for Personalized Cancer Therapy, professor of medicine, The University of Texas MD Anderson Cancer Center, discussed preliminary data with a novel combination in the treatment of patients with renal cell carcinoma.

May 22, 2019

The University of Texas MD Anderson Cancer Center named David Jaffray, PhD, as its first-ever chief technology and digital officer.

May 21, 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the biology of right- versus left-sided colorectal cancer.

May 16, 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

May 15, 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of early genomic testing in patients with colorectal cancer.

May 13, 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the significance of tumor sidedness in colorectal cancer.

May 11, 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses the utility of liquid biopsies in non–small cell lung cancer (NSCLC).

May 08, 2019

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the molecular understanding of clear cell renal cell carcinoma (RCC).

May 07, 2019

Scott Kopetz, MD, PhD, FACP, explains the biologic difference between left- and right-sided colorectal cancer and highlights recent research on tumor sidedness and its impact on clinical practice.

April 26, 2019

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses tailoring approaches to molecular subsets of patients with metastatic colorectal cancer.

April 25, 2019

Tagraxofusp led to a 90% overall response rate as a first-line therapy in patients with blastic plasmacytoid dendritic cell neoplasm.

April 24, 2019

Eric Jonasch, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses the use of single-agent pembrolizumab in the treatment of patients with metastatic non–clear cell renal cell carcinoma.

April 24, 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of personalized care in patients with metastatic colorectal cancer.

April 19, 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses unmet needs with immunotherapy in metastatic colorectal cancer.

April 19, 2019

Michael J. Overman, MD, discusses an immunotherapy combination regimen in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.

April 18, 2019

Mariana Chavez Mac Gregor, MD, MSc, discussex recent shifts in the treatment of patients with metastatic triple-negative breast cancer.

April 17, 2019

Cathy Eng, MD, professor of gastrointestinal and medical oncology, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the BEACON CRC study in patients with BRAF-mutated colorectal cancer.